About Dr Darrin Disley
Darrin is a parallel entrepreneur, angel investor and enterprise champion. He is currently CEO of Horizon Discovery Group plc a company he has led from a $150k seed funding in March 2008 to a record $113 million IPO on AIM six years later and a current market capitalisation of >$500 million. He has been involved in the start-up and growth of numerous business ventures securing >$425 million business financing as well as closing >$585 million of commercial deals.
In 2012, he was named Business Leader of the Year at the European Life Science Awards, in 2014 Global Executive of the Year by Scrip, in 2015 was named UK Quoted Company Entrepreneur of the Year, Cambridge Business Person of the Year, 1 of the 175 Faces of Chemistry by the Royal Society of Chemistry and in 2017 he was named UK Public Company
CEO of the Year at the Biotech and Money Awards Darrinsupports education, entrepreneurship and mentoring programs in the UK via the Professor Christopher R Lowe Carpe Diem Enterprise Fund and has backed over 30 start-up life science, technology and social enterprises. This led to him recently being conferred with a lifetime-held Queens Award for Enterprise Promotion in the 2016 birthday honours list. He is an Honorary Fellow at the Judge Business School and Enterprise Fellow at the Department of Chemical Engineering and Institute of Biotechnology both at the University of Cambridge and an Honorary Visiting Fellow at the University of Salford. He is currently Director and co-founder of Avvinity Therapeutics Ltd and GeoSpock Ltd, Chairman of Desktop Genetics Ltd, Director of Celixir plc and HealX Ltd, Board Member of the UK Bioindustry Association, Chairman of Trustees at Footprint Cafes CIO and serves on the advisory boards of Axol Bioscience Ltd, Biotech and Money, the Cambridge Science Centre, the Cambridge Phenomenon, Elpis Biomedical and SimPrints.